InvestorsHub Logo
Followers 26
Posts 4067
Boards Moderated 0
Alias Born 12/26/2018

Re: Barron4664 post# 269146

Monday, 07/29/2019 6:16:54 PM

Monday, July 29, 2019 6:16:54 PM

Post# of 403169
Right. But there would need to be a reason to believe such a $3 billion market cap would be justified.

Assume the market suddenly decides this year that B-UP will succeed and sell $300M/year (very very bullish sales case).

$300M/year * 6% = $18M/year in royalties.

Add a 5 year multiple to these and our royalties on B-UP are worth $90M. Add the $24M in milestones and that brings you to $114M B-UP total projected revenue. We won't see more than $6M of that for at least 3 years though.

Let's call the upfront payment $30M.

Cash: $30M

B-ABSSSI: ?
How much is this worth? The phase 3 is pretty much a guaranteed success based on the phase 2b results. $30M to run it or so. We have completely derisked this one.

B-OM: ?
Hard to value. The drug is effective and safe. It has the superior delivery method among all potential competitors.

Kevetrin: ?
B-UC: ?
B-IBD: ?
B-UP: $114M

Just curious how you get the values to add up to $3B in the next two months. Speculation could bring us to $300M if there is evidence that the upfront payment was $30M. $3B though?

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News